Education
About Us
Working with TipRanks
Follow Us
Precision BioSciences (DTIL)
NASDAQ:DTIL
DTIL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.61 - $10.71
Previous CloseN/A
Volume55.33K
Average Volume (3M)84.71K
Market Cap
$59.29M
Enterprise Value$13.60M
Total Cash (Recent Filing)$62.24M
Total Debt (Recent Filing)$29.45M
Price to Earnings (P/E)2.4
Beta1.18
Next Earnings
Nov 11, 2025EPS Estimate
-1.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding11,786,991
10 Day Avg. Volume68,949
30 Day Avg. Volume84,714
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.23
Enterprise Value/Revenue10.78
Enterprise Value/Gross Profit24.07
Enterprise Value/Ebitda-0.18
Forecast
1Y Price Target
$36.33Price Target Upside616.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Financial StabilityPrecision Biosciences has a cash runway into the second half of 2027, indicating financial stability and the ability to advance its programs.
Innovative TreatmentsPrecision's targeting of cccDNA is potentially curative for chronic hepatitis B, offering an innovative approach where current treatments only suppress the disease.
Regulatory ApprovalsPrecision was granted FDA rare pediatric disease and orphan drug designation for PBGENE-DMD for the treatment of DMD.
Bears Say
Antigen UpregulationThere was a compensatory upregulation of antigens (HBsAg) in two patients, causing their levels to return to baseline.
Efficacy ConcernsCurrent dose levels in human trials are significantly lower than those that showed over 90% antigen reduction in animal studies, indicating a gap in efficacy.
Precision BioSciences News
DTIL FAQ
What was Precision BioSciences’s price range in the past 12 months?
Precision BioSciences lowest stock price was $3.61 and its highest was $10.71 in the past 12 months.
What is Precision BioSciences’s market cap?
Precision BioSciences’s market cap is $59.29M.
When is Precision BioSciences’s upcoming earnings report date?
Precision BioSciences’s upcoming earnings report date is Nov 11, 2025 which is in 65 days.
How were Precision BioSciences’s earnings last quarter?
Precision BioSciences released its earnings results on Aug 06, 2025. The company reported -$2.13 earnings per share for the quarter, missing the consensus estimate of -$1.5 by -$0.63.
Is Precision BioSciences overvalued?
According to Wall Street analysts Precision BioSciences’s price is currently Undervalued.
Does Precision BioSciences pay dividends?
Precision BioSciences does not currently pay dividends.
What is Precision BioSciences’s EPS estimate?
Precision BioSciences’s EPS estimate is -1.49.
How many shares outstanding does Precision BioSciences have?
Precision BioSciences has 11,786,991 shares outstanding.
What happened to Precision BioSciences’s price movement after its last earnings report?
Precision BioSciences reported an EPS of -$2.13 in its last earnings report, missing expectations of -$1.5. Following the earnings report the stock price went down -1.029%.
Which hedge fund is a major shareholder of Precision BioSciences?
Currently, no hedge funds are holding shares in DTIL
Precision BioSciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.33 (616.57% Upside)
$36.33 (616.57% Upside)
Hedge Fund Trend
Decreased
By 426.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $28.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.89%
12-Months-Change
Fundamentals
Return on Equity
-143.89%
Trailing 12-Months
Asset Growth
-34.30%
Trailing 12-Months
Company Description
Precision BioSciences
Precision BioSciences, Inc. (DTIL) is a biotechnology company that specializes in gene editing and genetic therapies. The company operates primarily in the life sciences sector, focusing on developing innovative solutions for various diseases, including cancer and genetic disorders. Precision BioSciences utilizes its proprietary ARCUS technology, a genome editing platform designed to create precise and efficient edits in DNA, enabling the development of therapies that can potentially transform treatment paradigms. The company collaborates with academic institutions and biopharmaceutical companies to advance its research and therapeutic candidates.
DTIL Stock 12 Month Forecast
Average Price Target
$36.33
▲(616.57% Upside)
Technical Analysis
Bluebird Bio
―
CytomX Therapeutics
―
Adicet Bio
―
ImageneBio
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
3.41% Insiders
4.15% Mutual Funds
26.67% Other Institutional Investors
62.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---